In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 20632-12-6, name is 1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)propan-1-one, introducing its new discovery. Application In Synthesis of 1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)propan-1-one
CARBINOL DERIVATIVES HAVING CYCLIC LINKER
[Object] To provide a novel LXR.beta agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer’s disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 20632-12-6, and how the biochemistry of the body works.Application In Synthesis of 1-(2,3-Dihydrobenzo[b][1,4]dioxin-6-yl)propan-1-one
Reference£º
Benzodioxan,
1,4-Benzodioxane | C8H8O2 – PubChem